WuXi AppTec
2359
Performance
About WuXi AppTec
WuXi AppTec is a global contract research, development and manufacturing organization (CRDMO) that provides integrated R&D and manufacturing services for the pharmaceutical and life sciences industries. With operations across Asia, Europe, and North America, the company offers end-to-end capabilities spanning drug discovery, development, and manufacturing to enable partners to bring therapies to patients. WuXi AppTec collaborates with thousands of partners across 30+ countries, emphasizing high-quality, compliant processes and a platform-based approach to enable innovation in healthcare.
Recent News
Asian Marco Initial Thoughts: US/Iran Stand-Off the Main Focus; Oil Price Rising. Warsh Nomination for Fed Chair to Be Voted on Wednesday, Central Banks Rate Decisions in Focus This Week.
Thermo Fisher, Charles River Workforce Cuts; WuXi Signs Contract with Vertex
#JPM26: Day 3 at the JP Morgan Healthcare Conference
China Weekly Wrap: Cambricon Earnings Edition
Stock Trader’s Guide to Navigating High Stakes Trump-Xi Talks
SEC Drops Climate Disclosure Rule as EU Offers $5 B Carbon Relief, Shaping ClimateTech Landscape
US Adds Alibaba, BYD and Other Chinese Tech Champions to Military Company Blacklist
Onepot AI Raises $13M to Help Make Chemical Drug Creation Easier
WuXi AppTec Q1 Profit Jumps 31% on Booming CRO and Manufacturing Demand
Mapping the Next Phase of Analytical Innovation for ADCs
Pentagon Bars Alibaba, Baidu, BYD From U.S. Defense Contracts in Expanded Military List
Hillhouse Targets $8bn Asia-Focused Fundraising
US Targets China’s Military-Tech Firm Ties While Forging Its Own
Recent Deals
No recent deals for this company.